RIMFROST AS has published a randomized, single-dose, cross-over trial in Lipids in Health and Disease which documents the bioavailability of fatty acids from RIMFROST krill products and fish oil in healthy humans.
Olympic Seafood AS, a fishing company based on the Norwegian west coast, has published a randomized, single-dose, cross-over trial in Lipids in Health and Disease* which documents the bioavailability of fatty acids from RIMFROST krill products and fish oil in healthy humans. Olympic Seafood owns the brand RIMFROST.
In a randomized, single-dose, single-blind, cross-over, active-reference trial in 15 healthy subjects, the 72-hour bioavailability of approx. 1 700 mg EPA plus DHA in krill oil to krill meal and fish oil was compared. Primary endpoint was the incremental area under the curve in plasma phospholipid fatty acids, reflecting recent dietary intake. According to the primary endpoint, EPA plus DHA had a significantly higher bioavailability in krill oil, as compared to krill meal and fish oil.
“The participants were instructed to take the supplements with a standard breakfast. Under these conditions it was clear that fish oil was not very well absorbed and that krill oil was the superior source of EPA/DHA. RIMFROST SUBLIME has a very high level of intact phospholipids, suggesting that phospholipids and not free fatty acids are responsible for the higher bioavailability found” according to Dr. Inge Bruheim of Olympic Seafood. “These intriguing results will be followed up in new clinical trials which are targeting longer-term parameter of omega-3 fatty acid bioavailability.” said Dr. Bruheim.
The steel cutting ceremony at Tersan shipyard in Turkey was held at August 20, on our new krill vessel - we are excited!
Høyesteretts ankeutvalg avviste i dag anken fra Aker Biomarine i saken mot krillselskapet Rimfrost. Dermed er det endelig fastslått at patenter for produksjon av krillprodukter tilhører Rimfrost.
Krillselskapet Rimfrost har fått fullt medhold i ankesaken i Frostating lagmannsrett, der Aker Biomarine anla mot Rimfrost knyttet til patenter for krillforedling.
The U.S. Patent and Trademark Office Patent Trial and Appeal Board (PTAB) has found another patent related to krill oil production, owned by Aker Biomarine, unpatentable.
Norwegian krill processor Rimfrost has awarded a contract to Westcon for building a new krill fishing vessel worth more than NOK 1 billion. The maritime cluster in Sunnmøre and other Norwegian enterprises stand to secure almost NOK 500 million in orders from the project.
Krillprodusenten Rimfrost inngår kontrakt med verftsgruppen Westcon om bygging av nytt krillfartøy til over en milliard norske kroner. Den maritime klyngen på Sunnmøre og andre norske virksomheter vil få oppdrag for nærmere en halv milliard kroner som følge av byggingen.
The Court of Appeals for the Federal Circuit has affirmed two earlier rulings from the Patent Trial and Appeal Board (PTAB), finding all claims of two patents from Aker Biomarine unpatentable.
The US Patent & Trademark Office (USPTO) has found for krill oil specialist RIMFROST AS on all counts in yet another case against Aker Biomarine. This is the seventh legal proceeding between the companies which Aker has either lost or withdrawn.
On the 20th of December 2018 the Directorate of Fisheries in Norway awarded a second license for krill harvest in Antarctica to RIMFROST.
New clinical study finds that RIMFROST krill oil significantly reduces glucose in healthy humans
The US patent authorities have found that patents related to krill oil and its production held by Aker Biomarine are unpatentable.
Meet the RIMFROST team at Vitafoods in Geneva from May 15th to May 17th at stand #M140
Stig Remøy continues the growth of RIMFROST and hires Karl-Erik Slinning as new Commercial Director
RIMFROST AS seeks a Commercial Director who can help propel the company forward. Take a look at this great opportunity in a company in growth.
The RIMFROST team celebrates great results and increased sales in 2017! We continue to deliver supreme quality products!
To increase knowledge about the biological effects and mechanism of actions of proteins and lipids derived from krill, the company has established a long-term collaboration with the University of Bergen in Norway.
Rimfrost is in the planning and design phase for the construction of a new krill vessel. The vessel will be equipped to serve multiple market segments. The process facility in the new vessel will be based on patents owned by Rimfrost.
Rimfrost AS, a Norwegian biotechnology company which supplies its RIMFROST Sublime krill oil to the world’s food supplement markets, announced today that the U.S. Patent & Trademark Office issued four (4) decisions finding that a reasonable likelihood exists that every claim of two (2) patents owned to Aker Biomarine Antarctic AS are unpatentable.
In their second quarter report 2017, Aker ASA misinforms the market about Aker Biomarines ownership in patents and intellectual property rights in connection with the purchase of F/T Juvel.
Norwegian krill manufacturer RIMFROST notes that the global demand for krill oil for human consumption increases, and begins the planning of a new vessel. “After several challenging years, the global krill market is now showing real signs of recovery”, owner of RIMFROST, Stig Remøy, says.
RIMFROST AS is a Norwegian biotechnology company which supplies its RIMFROST Sublime krill oil to the world’s food supplement markets. The company is experiencing increasing sales and market share growth, especially the USA and Europe. The strategy of RIMFROST is now to expand into China and offer a high quality krill oil with superior color and viscosity which meets the regulatory requirements of Chinese authorities. As a first step RIMFROST has been successful in obtaining regulatory approval from the National Health and Family Planning Commission (NHFMC).
Yesterday, Aker Biomarine voluntarily withdrew its complaint at the International Trade Commission (ITC), alleging that krill manufacturer Rimfrost had violated several of its patents.
As the Holiday Season is upon us, the RIMFROST TEAM wants to wish you a very Merry Christmas and a New Year filled with peace and prosperity.
We are attending this years Supply Side West show and hope to see you there. Stop by our booth #PP165 and lets talk krill.
RIMFROST in collaboration with partners in New Zealand has developed and patented a krill powder for human nutraceutical applications. In a long term collaboration with the University in Bergen, with the financial support from the Norwegian Research Council, krill products have been tested in animal models and in humans and the results have been published in international scientific journals. The most recent data shows that krill powder is effective in reducing atherosclerosis in apo E-/- mice, suggesting that it also may be effective in improving vascular health in humans.
RIMFROST AS is a Norwegian vertically integrated krill company which offers krill oil and krill powder to worlds food supplement markets. The company’s strategy to offer this product in South America has now reached a milestone as the company has been granted regulatory approval in Brazil.
RIMFROST AS is a Norwegian vertically integrated biotechnology company that operates and controls the production of high quality krill products from raw material to finished capsules. The company’s recent innovation, a 100% pure krill oil extract with 60% phospholipids, has now obtained a favourable opinion from the Finnish Novel Food Board based on substantial equivalence and is therefore ready for the European market.
In a collaboration with NOFIMA and Denmark Technical University, two stability studies have been performed, showing that the krill powder is stable and minimal degradation takes place.
RIMFROST AS has published a randomized, single-dose, cross-over trial in Lipids in Health and Disease which documents the bioavailability of fatty acids from RIMFROST krill products and fish oil in healthy humans.
Olympic Seafood AS has today received confirmation that its krill fishery is now certified by the Marine Stewardship Council (MSC).
